MarketLens
Sign Up

What's Driving AnaptysBio's Strategic Spin-Off

7 months ago
SHARE THIS ON:

What's Driving AnaptysBio's Strategic Spin-Off

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 week ago

Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere

Several biotechs are proceeding with IPOs and trading well while investors await Anthropic's official IPO filing, signaling steady demand for biotech listings even as a marquee tech name stays pending...
Stock News•3 weeks ago

Caribou Biosciences to Evaluate Strategic Alternatives

Caribou Biosciences will evaluate strategic alternatives and discontinue its vispa-cel and CB-011 allogeneic CAR-T programs, a move aimed at maximizing stockholder value.
Stock News•3 months ago

AnaptysBio: The Royalty Waterfall Is About To Reverse

AnaptysBio's value now hinges on Jemperli royalties from GSK, with a 95% targeted EBIT margin and over $140M net cash. Royalty retention will rise after the Sagard obligation is paid by mid-2027.

Breaking News

View All →

Top Headlines

View More →
Stock News•3 hours ago

In 1999, A Recently Divorced Masseuse Took A Gig At A Tiny Start-Up For $45 An Hour Plus Stock Options. The Name Of The Start-Up Was Google.

Stock News•3 hours ago

Tech Trepidation: Mag 7 Cash Flow, Guidance & Fed Concerns Hit AI Trade

Stock News•5 hours ago

Chevron: 3 Key Takeaways for Long-Term Investors

Stock News•6 hours ago

S&P Says Meta Can't Make Money From AI as Well as Its Rivals

Stock News•6 hours ago

France Wants a 5.5-Cent-per-Gigabyte Tax on Netflix, Google and Meta